MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- ASTRAZENECA PHARMA
ASTRAZENECA PHARMA Share Price (AIDL)
Here is the latest stock price and chart of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
EXPIRES at 11:59pm: Our Urgent Broadcast on India's Revival
| Live BSE Quotes | Jun 14, 2021 11:22:00 AM | ||
|---|---|---|---|
| Price (Rs)3,823.25 | Open (Rs) 3,782.95 | High (Rs) 3,898.65 | Low (Rs) 3,741.60 |
| % Change1.19 | Volume 3,893 | Value (Rs) 14,883,912 | 52-Week H/L 4,970.00 / 3,000.00 |
| Live NSE Quotes | Jun 14, 2021 11:24:56 AM | ||
|---|---|---|---|
| Price (Rs)3,816.20 | Open (Rs) 3,780.40 | High (Rs) 3,900.00 | Low (Rs) 3,740.00 |
| % Change0.95 | Volume 73,312 | Value (Rs) 282,011,470 | 52-Week H/L 4,970.00 / 3,005.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day 1.19% | 1 Month -0.44% | 3 Months 15.46% | 1 Year 11.46% | 5 Years (CAGR)* 29.77% | 10 Years (CAGR)* 10.93% |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 30.24 | P/E Ratio (x) 126.43 | Market Cap (Rs m) 95,581.25 | P/BV (x) 38.71 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
ASTRAZENECA PHARMA Share Price Today:
ASTRAZENECA PHARMA share price is up 1.2% to Rs 3,823.3 on the BSE. On the NSE, the ASTRAZENECA PHARMA share price is up 0.9% to Rs 3,816.2. The total volume of shares traded is 0.1 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading down by 0.1%. And the benchmark S&P BSE SENSEX is at 52,182.3 (down 0.6%).
Over the last 30 days, the ASTRAZENECA PHARMA share price is up 1.0%. And over the last one year, ASTRAZENECA PHARMA share price is up 11.4%.
The current market capitalisation of ASTRAZENECA PHARMA stands at Rs 95,581.25 m. For more information, check out the list of top 100 companies in India in terms of market cap.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Falls 300 Points, Nifty Below 15,700; Adani Group Stocks Tumble(09:30 am)
Asian stock markets are mixed today in holiday-thinned trading as investors prepared for a key Federal Reserve meeting later in the week.
Related Views On News
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)
Sep 22, 2020 | Updated on Sep 22, 2020For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Why Did Shares of Divi's Lab Rally Today? (Views On News)
Jun 10, 2021The stock jumped 3.6% in intraday trade to hit its 52-week high.
Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)
Jun 8, 2021Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.
Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)
Jun 8, 2021Here's a rundown on the latest quarterly results of Jubilant Pharmova.
More Views on NewsMost Popular
Hotel Stocks Will Reward Investors (Fast Profits Daily)
Jun 8, 2021This is why I'm bullish on the hotel and hospitality sector.
Don't Break These 5 Intraday Trading Rules (Fast Profits Daily)
Jun 1, 2021To become a better intraday trader, follow these rules religiously.
The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)
Jun 9, 2021Investing in the best stocks could result in wealth compounding on a massive scale.
Rs 2 Trillion Stimulus Coming to a Stock Market Near You (Profit Hunter)
Jun 2, 2021Get ready to profit from a massive stimulus that you've never seen before.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 8-QTR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.